Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus ex vivo rinse in liver transplantation
NCT01564095Phase 3Terminated
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Oct 2011
- Primary completion
- Jul 2013
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tacrolimus in ischemia-reperfusion injury (IRI) (2 arms), sponsored by Ludwig Maximilian University of Munich. Primary endpoint: Maximum serum ALT-level at 48 hours. Started Oct 2011; status: terminated.
02
Drugs
tacrolimus
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT01564095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01564095.